BG64563B1 - Пептиди, метод за получаване и използването им - Google Patents

Пептиди, метод за получаване и използването им Download PDF

Info

Publication number: BG64563B1
Authority: BG; Bulgaria
Prior art keywords: nhc; nhch; residue; pro; och
Prior art date: 1995-12-15

Application number

BG102479A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102479A (en

Inventor

Wilhelm Amberg

Teresa Barlozzari

Harald Bernard

Ernst Buschmann

Andreas Haupt

Hans-Guenther Hege

Bernd Janssen

Andreas Kling

Helmut Lietz

Kurt Ritter

Martina Ullrich

Juergen Weymann

Thomas Zierke

Original Assignee

Basf Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-15

Filing date

1998-05-22

Publication date

2005-07-29

1998-05-22 Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft

1999-06-30 Publication of BG102479A publication Critical patent/BG102479A/xx

2005-07-29 Publication of BG64563B1 publication Critical patent/BG64563B1/bg

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 37
238000000034 method Methods 0.000 title claims abstract description 27
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 20
238000002360 preparation method Methods 0.000 title claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 32
150000001413 amino acids Chemical class 0.000 claims description 24
-1 N-methyl-valyl residue Chemical group 0.000 claims description 20
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 13
239000003153 chemical reaction reagent Substances 0.000 claims description 9
230000008878 coupling Effects 0.000 claims description 9
238000010168 coupling process Methods 0.000 claims description 9
238000005859 coupling reaction Methods 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 7
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 7
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
125000006239 protecting group Chemical group 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
238000003786 synthesis reaction Methods 0.000 claims description 5
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 4
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 4
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 claims description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
230000001613 neoplastic effect Effects 0.000 claims description 3
239000012299 nitrogen atmosphere Substances 0.000 claims description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
FNQIGYRDLYROLW-UHFFFAOYSA-N 1-hydroxy-2h-1,2,3-benzotriazine Chemical compound C1=CC=C2N(O)NN=CC2=C1 FNQIGYRDLYROLW-UHFFFAOYSA-N 0.000 claims description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
102000007079 Peptide Fragments Human genes 0.000 claims description 2
108010033276 Peptide Fragments Proteins 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000036185 rubor Effects 0.000 claims description 2
239000007791 liquid phase Substances 0.000 claims 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
239000007821 HATU Substances 0.000 claims 1
SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
125000006242 amine protecting group Chemical group 0.000 claims 1
210000004899 c-terminal region Anatomy 0.000 claims 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
125000002114 valyl group Chemical group 0.000 claims 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
229940024606 amino acid Drugs 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
239000000243 solution Substances 0.000 description 22
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000012074 organic phase Substances 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000010647 peptide synthesis reaction Methods 0.000 description 8
108010077112 prolyl-proline Proteins 0.000 description 8
239000002904 solvent Substances 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
229910052763 palladium Inorganic materials 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000037396 body weight Effects 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
RRWZZMHRVSMLCT-UHFFFAOYSA-N 2-(butylazaniumyl)acetate Chemical compound CCCCNCC(O)=O RRWZZMHRVSMLCT-UHFFFAOYSA-N 0.000 description 3
230000005526 G1 to G0 transition Effects 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000005304 joining Methods 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 2
102400001240 Inter-alpha-trypsin inhibitor light chain Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
APGLTERDKORUHK-LURJTMIESA-N N,N-dimethyl-L-Valine Chemical compound CC(C)[C@H](N(C)C)C(O)=O APGLTERDKORUHK-LURJTMIESA-N 0.000 description 2
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000008098 formaldehyde solution Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920000307 polymer substrate Polymers 0.000 description 2
238000005932 reductive alkylation reaction Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 1
NNEHOKZDWLJKHP-LBPRGKRZSA-N (2s)-3-methyl-2-[methyl(phenylmethoxycarbonyl)amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)N(C)C(=O)OCC1=CC=CC=C1 NNEHOKZDWLJKHP-LBPRGKRZSA-N 0.000 description 1
AUACPLOGXSJUHE-ZETCQYMHSA-N (2s)-n-propan-2-ylpyrrolidine-2-carboxamide Chemical compound CC(C)NC(=O)[C@@H]1CCCN1 AUACPLOGXSJUHE-ZETCQYMHSA-N 0.000 description 1
OQJJVXKMPUJFJK-BQBZGAKWSA-N (2s,3s)-2-(dimethylamino)-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N(C)C)C(O)=O OQJJVXKMPUJFJK-BQBZGAKWSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
XUWHRJBRJWTAPR-UHFFFAOYSA-N 2-(diethylazaniumyl)-3-methylbutanoate Chemical compound CCN(CC)C(C(C)C)C(O)=O XUWHRJBRJWTAPR-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 1
KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
XNNPAWRINYCIHL-UHFFFAOYSA-N 3-carbamoyl-PROXYL Chemical compound CC1(C)CC(C(N)=O)C(C)(C)N1[O] XNNPAWRINYCIHL-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
UIVWXNPUCAHAJX-UHFFFAOYSA-N 4-hydroxy-1,1-dioxo-2,5-diphenylthiophen-3-one Chemical compound O=S1(=O)C(C=2C=CC=CC=2)C(=O)C(O)=C1C1=CC=CC=C1 UIVWXNPUCAHAJX-UHFFFAOYSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
UOJYYXATTMQQNA-UHFFFAOYSA-N Proxan Chemical compound CC(C)OC(S)=S UOJYYXATTMQQNA-UHFFFAOYSA-N 0.000 description 1
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
108010045524 dolastatin 10 Proteins 0.000 description 1
108010045552 dolastatin 15 Proteins 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960004979 fampridine Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG102479A 1995-12-15 1998-05-22 Пептиди, метод за получаване и използването им BG64563B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57342295A	1995-12-15	1995-12-15

Publications (2)

Publication Number	Publication Date
BG102479A BG102479A (en)	1999-06-30
BG64563B1 true BG64563B1 (bg)	2005-07-29

Family

ID=24291935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102479A BG64563B1 (bg)	1995-12-15	1998-05-22	Пептиди, метод за получаване и използването им

Country Status (30)

Country	Link
EP (2)	EP0866800B1 (de)
JP (1)	JP3939354B2 (de)
KR (1)	KR100463739B1 (de)
CN (1)	CN1127514C (de)
AR (1)	AR004382A1 (de)
AT (2)	ATE471944T1 (de)
AU (2)	AU731458B2 (de)
BG (1)	BG64563B1 (de)
BR (1)	BR9611987A (de)
CA (1)	CA2237721C (de)
CO (1)	CO4750840A1 (de)
CZ (1)	CZ296908B6 (de)
DE (2)	DE69633457T2 (de)
DK (1)	DK0866800T3 (de)
ES (1)	ES2229287T3 (de)
HR (1)	HRP960585A2 (de)
HU (1)	HU228275B1 (de)
IL (2)	IL124342A (de)
MX (1)	MX9803953A (de)
MY (1)	MY114327A (de)
NO (1)	NO319273B1 (de)
NZ (1)	NZ324691A (de)
PL (1)	PL186721B1 (de)
PT (1)	PT866800E (de)
RU (1)	RU2182911C2 (de)
SK (1)	SK285286B6 (de)
TR (1)	TR199801102T2 (de)
TW (1)	TW474946B (de)
WO (1)	WO1997022621A2 (de)
ZA (1)	ZA9610510B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143721A (en) *	1997-07-18	2000-11-07	Basf Aktiengesellschaft	Dolastatin 15 derivatives
US5985837A (en) *	1998-07-08	1999-11-16	Basf Aktiengesellschaft	Dolastatin 15 derivatives
WO2000051998A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en)	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US4879276A (en) *	1983-12-19	1989-11-07	Uniroyal Chemical Ltd./Uniroyal Chemical Ltee	Method for reducing serum uric acid levels
WO1993023424A1 (en) *	1992-05-20	1993-11-25	Basf Aktiengesellschaft	Derivatives of dolastatin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5831002A (en) *	1992-05-20	1998-11-03	Basf Aktiengesellschaft	Antitumor peptides
DE69329425T2 (de) *	1992-12-16	2001-01-18	Basf Ag	Dolastatin analog
DE4415998A1 (de) *	1994-05-06	1995-11-09	Basf Ag	Neue Tetrapeptide, ihre Herstellung Verwendung
DE4415997A1 (de) *	1994-05-06	1995-11-09	Basf Ag	Neuer peptidischer Wirkstoff und dessen Herstellung
US5807984A (en) *	1995-11-09	1998-09-15	Basf Aktienegesellschaft	Oligopeptides, the preparation and use thereof

1996
- 1996-12-09 TW TW085115211A patent/TW474946B/zh not_active IP Right Cessation
- 1996-12-11 AT AT04022451T patent/ATE471944T1/de not_active IP Right Cessation
- 1996-12-11 HU HU0000172A patent/HU228275B1/hu not_active IP Right Cessation
- 1996-12-11 PL PL96327175A patent/PL186721B1/pl unknown
- 1996-12-11 ES ES96943076T patent/ES2229287T3/es not_active Expired - Lifetime
- 1996-12-11 CN CN96198992A patent/CN1127514C/zh not_active Expired - Fee Related
- 1996-12-11 BR BR9611987A patent/BR9611987A/pt not_active Application Discontinuation
- 1996-12-11 DE DE69633457T patent/DE69633457T2/de not_active Expired - Lifetime
- 1996-12-11 DK DK96943076T patent/DK0866800T3/da active
- 1996-12-11 RU RU98113945/04A patent/RU2182911C2/ru not_active IP Right Cessation
- 1996-12-11 WO PCT/EP1996/005518 patent/WO1997022621A2/en not_active Ceased
- 1996-12-11 EP EP96943076A patent/EP0866800B1/de not_active Expired - Lifetime
- 1996-12-11 IL IL12434296A patent/IL124342A/xx not_active IP Right Cessation
- 1996-12-11 DE DE69638206T patent/DE69638206D1/de not_active Expired - Lifetime
- 1996-12-11 AU AU11925/97A patent/AU731458B2/en not_active Ceased
- 1996-12-11 EP EP04022451A patent/EP1593686B1/de not_active Expired - Lifetime
- 1996-12-11 TR TR1998/01102T patent/TR199801102T2/xx unknown
- 1996-12-11 NZ NZ324691A patent/NZ324691A/xx not_active IP Right Cessation
- 1996-12-11 CA CA002237721A patent/CA2237721C/en not_active Expired - Fee Related
- 1996-12-11 JP JP52248197A patent/JP3939354B2/ja not_active Expired - Fee Related
- 1996-12-11 PT PT96943076T patent/PT866800E/pt unknown
- 1996-12-11 CZ CZ0184698A patent/CZ296908B6/cs not_active IP Right Cessation
- 1996-12-11 KR KR10-1998-0704456A patent/KR100463739B1/ko not_active Expired - Fee Related
- 1996-12-11 AT AT96943076T patent/ATE277076T1/de active
- 1996-12-11 SK SK767-98A patent/SK285286B6/sk not_active IP Right Cessation
- 1996-12-12 HR HR08/573,422A patent/HRP960585A2/hr not_active Application Discontinuation
- 1996-12-13 MY MYPI96005266A patent/MY114327A/en unknown
- 1996-12-13 CO CO96065733A patent/CO4750840A1/es unknown
- 1996-12-13 AR ARP960105673A patent/AR004382A1/es active IP Right Grant
- 1996-12-13 ZA ZA9610510A patent/ZA9610510B/xx unknown
1998
- 1998-05-19 MX MX9803953A patent/MX9803953A/es active IP Right Grant
- 1998-05-22 BG BG102479A patent/BG64563B1/bg unknown
- 1998-06-12 NO NO19982711A patent/NO319273B1/no not_active IP Right Cessation
2004
- 2004-10-15 AU AU2004220772A patent/AU2004220772B2/en not_active Ceased
2005
- 2005-02-14 IL IL166853A patent/IL166853A/en not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4879276A (en) *	1983-12-19	1989-11-07	Uniroyal Chemical Ltd./Uniroyal Chemical Ltee	Method for reducing serum uric acid levels
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
WO1993023424A1 (en) *	1992-05-20	1993-11-25	Basf Aktiengesellschaft	Derivatives of dolastatin

Also Published As

Publication number	Publication date
HUP0000172A2 (en)	2000-07-28
TR199801102T2 (xx)	1998-12-21
PL186721B1 (pl)	2004-02-27
DK0866800T3 (da)	2005-01-17
AU1192597A (en)	1997-07-14
EP0866800A2 (de)	1998-09-30
MX9803953A (es)	1998-09-30
AU2004220772A1 (en)	2004-11-11
BG102479A (en)	1999-06-30
NO319273B1 (no)	2005-07-11
HU228275B1 (en)	2013-02-28
CA2237721A1 (en)	1997-06-26
ES2229287T3 (es)	2005-04-16
EP1593686A1 (de)	2005-11-09
CZ184698A3 (cs)	1998-09-16
HRP960585A2 (en)	1998-02-28
AU731458B2 (en)	2001-03-29
BR9611987A (pt)	1999-02-17
HUP0000172A3 (en)	2000-09-28
CN1204342A (zh)	1999-01-06
NO982711D0 (no)	1998-06-12
DE69638206D1 (de)	2010-08-05
ATE277076T1 (de)	2004-10-15
IL124342A0 (en)	1998-12-06
NO982711L (no)	1998-06-12
IL124342A (en)	2005-06-19
RU2182911C2 (ru)	2002-05-27
EP0866800B1 (de)	2004-09-22
DE69633457D1 (de)	2004-10-28
NZ324691A (en)	1999-11-29
JP3939354B2 (ja)	2007-07-04
ZA9610510B (en)	1998-06-15
ATE471944T1 (de)	2010-07-15
SK285286B6 (sk)	2006-10-05
KR20000064400A (ko)	2000-11-06
CO4750840A1 (es)	1999-03-31
MY114327A (en)	2002-09-30
WO1997022621A3 (en)	1998-02-26
AR004382A1 (es)	1998-11-04
DE69633457T2 (de)	2005-09-22
CZ296908B6 (cs)	2006-07-12
CN1127514C (zh)	2003-11-12
TW474946B (en)	2002-02-01
JP2000502092A (ja)	2000-02-22
IL166853A (en)	2013-03-24
AU2004220772B2 (en)	2008-06-12
EP1593686B1 (de)	2010-06-23
CA2237721C (en)	2008-01-29
SK76798A3 (en)	1999-02-11
WO1997022621A2 (en)	1997-06-26
PL327175A1 (en)	1998-11-23
PT866800E (pt)	2005-01-31
KR100463739B1 (ko)	2005-02-28

Publication	Publication Date	Title
US5502032A (en)	1996-03-26	Peptides, the preparation and use thereof
AU725164B2 (en)	2000-10-05	Novel dolastatin derivatives, their preparation and use
WO1993023424A1 (en)	1993-11-25	Derivatives of dolastatin
BG64563B1 (bg)	2005-07-29	Пептиди, метод за получаване и използването им
US8440626B2 (en)	2013-05-14	Antineoplastic peptides
AU775090B2 (en)	2004-07-15	Antineoplastic peptides
HK1080871A (en)	2006-05-04	Antineoplastic peptides
SK165497A3 (en)	1998-08-05	Peptides, preparation method thereof and pharmaceutical composition containing the same